Publications
2020
Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients.
Davies, A., Rodriguez-Vicente, A. E., Austin, G., Loaiza, S., Foroni, L., Clark, R. E., & Pirmohamed, M. (2020). Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients.. Scientific reports, 10(1). doi:10.1038/s41598-020-65350-0
2018
MECHANISMS OF CHEMOTHERAPY-INDUCED DIARRHOEA
French, S., Davies, A., & Pirmohamed, M. (2018). MECHANISMS OF CHEMOTHERAPY-INDUCED DIARRHOEA. In GUT Vol. 67 (pp. A159). doi:10.1136/gutjnl-2018-BSGAbstracts.315
2017
Mechanisms of Chemotherapy-Induced Diarrhoea
French, S., Davies, A., & Pirmohamed, M. (2017). Mechanisms of Chemotherapy-Induced Diarrhoea. In DRUG SAFETY Vol. 40 (pp. 1025-1026). Retrieved from https://www.webofscience.com/
Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury
Carr, D. F., Ayehunie, S., Davies, A., Duckworth, C. A., French, S., Hall, N., . . . Pirmohamed, M. (2017). Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. PHARMACOLOGY & THERAPEUTICS, 172, 181-194. doi:10.1016/j.pharmthera.2017.01.002
2014
Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia
Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176
The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia
Giannoudis, A., Davies, A., Harris, B., Lucas, C., Pirmohamed, M., & Clark, R. (2014). The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia, 28(6), 1360-1363. doi:10.1038/leu.2014.38
2013
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035
The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia
Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.
2012
Lamotrigine is a substrate for OCT1 in brain endothelial cells
Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. BIOCHEMICAL PHARMACOLOGY, 83(6), 805-814. doi:10.1016/j.bcp.2011.12.032
2010
Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography
Davies, A., Hayes, A. K., Knight, K., Watmough, S. J., Pirmohamed, M., & Clark, R. E. (2010). Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. LEUKEMIA RESEARCH, 34(6), 702-707. doi:10.1016/j.leukres.2009.11.009
2009
Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). Chronic myeloid leukemia patients with the e13a2 <i>BCR</i>-<i>ABL</i> fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(10), 1362-1367. doi:10.3324/haematol.2009.009134
Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., Harris, R. J., . . . Mountford, J. C. (2009). Nilotinib concentration in cell lines and primary CD34<SUP>+</SUP> chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. LEUKEMIA, 23(11), 1999-2006. doi:10.1038/leu.2009.166
2008
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. BLOOD, 112(8), 3348-3354. doi:10.1182/blood-2007-10-116236
Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia
Clark, R. E., Davies, A., Pirmohamed, M., & Giannoudis, A. (2008). Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. LEUKEMIA & LYMPHOMA, 49(4), 639-642. doi:10.1080/10428190701858823